A RANDOMIZED, OPEN-LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NONSMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI-PD-(L)1 THERAPY AND CHEMOTHERAPY (COSTAR LUNG)

  • Moore, Maggie (Primary Chief Investigator (PCI))
  • Hawkins, Cheryl-Ann (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date12/05/21 → 31/12/26

Keywords

  • Lung cancer
  • Clinical trial
  • Chemotherapy